Literature DB >> 25193665

Structural basis for the binding specificity of human Recepteur d'Origine Nantais (RON) receptor tyrosine kinase to macrophage-stimulating protein.

Kinlin L Chao1, Natalia V Gorlatova1, Edward Eisenstein2, Osnat Herzberg3.   

Abstract

Recepteur d'origine nantais (RON) receptor tyrosine kinase and its ligand, serum macrophage-stimulating protein (MSP), play important roles in inflammation, cell growth, migration, and epithelial to mesenchymal transition during tumor development. The binding of mature MSPαβ (disulfide-linked α- and β-chains) to RON ectodomain modulates receptor dimerization, followed by autophosphorylation of tyrosines in the cytoplasmic receptor kinase domains. Receptor recognition is mediated by binding of MSP β-chain (MSPβ) to the RON Sema. Here we report the structure of RON Sema-PSI-IPT1 (SPI1) domains in complex with MSPβ at 3.0 Å resolution. The MSPβ serine protease-like β-barrel uses the degenerate serine protease active site to recognize blades 2, 3, and 4 of the β-propeller fold of RON Sema. Despite the sequence homology between RON and MET receptor tyrosine kinase and between MSP and hepatocyte growth factor, it is well established that there is no cross-reactivity between the two receptor-ligand systems. Comparison of the structure of RON SPI1 in complex with MSPβ and that of MET receptor tyrosine kinase Sema-PSI in complex with hepatocyte growth factor β-chain reveals the receptor-ligand selectivity determinants. Analytical ultracentrifugation studies of the SPI1-MSPβ interaction confirm the formation of a 1:1 complex. SPI1 and MSPαβ also associate primarily as a 1:1 complex with a binding affinity similar to that of SPI1-MSPβ. In addition, the SPI1-MSPαβ ultracentrifuge studies reveal a low abundance 2:2 complex with ∼ 10-fold lower binding affinity compared with the 1:1 species. These results support the hypothesis that the α-chain of MSPαβ mediates RON dimerization.
© 2014 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Analytical Ultracentrifugation; Macrophage-stimulating Protein; Protein-Protein Interaction; RON Receptor Tyrosine Kinase; Receptor Tyrosine Kinase; Signal Transduction; X-ray Crystallography

Mesh:

Substances:

Year:  2014        PMID: 25193665      PMCID: PMC4208004          DOI: 10.1074/jbc.M114.594341

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  70 in total

1.  Inhibition of MSP-RON signaling pathway in cancer cells by a novel soluble form of RON comprising the entire sema sequence.

Authors:  Qi Ma; Kun Zhang; Hang-Ping Yao; Yong-Qing Zhou; Snehal Padhye; Ming-Hai Wang
Journal:  Int J Oncol       Date:  2010-06       Impact factor: 5.650

Review 2.  RON, a tyrosine kinase receptor involved in tumor progression and metastasis.

Authors:  E Ramsay Camp; Wenbiao Liu; Fan Fan; Anthony Yang; Ray Somcio; Lee M Ellis
Journal:  Ann Surg Oncol       Date:  2005-03-15       Impact factor: 5.344

Review 3.  Structural insights into Met receptor activation.

Authors:  Hartmut H Niemann
Journal:  Eur J Cell Biol       Date:  2011-01-15       Impact factor: 4.492

4.  Gene-centric association mapping of chromosome 3p implicates MST1 in IBD pathogenesis.

Authors:  P Goyette; C Lefebvre; A Ng; S R Brant; J H Cho; R H Duerr; M S Silverberg; K D Taylor; A Latiano; G Aumais; C Deslandres; G Jobin; V Annese; M J Daly; R J Xavier; J D Rioux
Journal:  Mucosal Immunol       Date:  2008-01-16       Impact factor: 7.313

5.  The soluble sema domain of the RON receptor inhibits macrophage-stimulating protein-induced receptor activation.

Authors:  Debora Angeloni; Alla Danilkovitch-Miagkova; Alexei Miagkov; Edward J Leonard; Michael I Lerman
Journal:  J Biol Chem       Date:  2003-11-03       Impact factor: 5.157

6.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

7.  Identification of the ron gene product as the receptor for the human macrophage stimulating protein.

Authors:  M H Wang; C Ronsin; M C Gesnel; L Coupey; A Skeel; E J Leonard; R Breathnach
Journal:  Science       Date:  1994-10-07       Impact factor: 47.728

8.  Apical oxidative hyaluronan degradation stimulates airway ciliary beating via RHAMM and RON.

Authors:  Dahis Manzanares; Maria-Elena Monzon; Rashmin C Savani; Matthias Salathe
Journal:  Am J Respir Cell Mol Biol       Date:  2007-03-29       Impact factor: 6.914

9.  Protein characterization of a candidate mechanism SNP for Crohn's disease: the macrophage stimulating protein R689C substitution.

Authors:  Natalia Gorlatova; Kinlin Chao; Lipika R Pal; Rawan Hanna Araj; Andrey Galkin; Illarion Turko; John Moult; Osnat Herzberg
Journal:  PLoS One       Date:  2011-11-07       Impact factor: 3.240

10.  RON is a heterodimeric tyrosine kinase receptor activated by the HGF homologue MSP.

Authors:  G Gaudino; A Follenzi; L Naldini; C Collesi; M Santoro; K A Gallo; P J Godowski; P M Comoglio
Journal:  EMBO J       Date:  1994-08-01       Impact factor: 11.598

View more
  8 in total

Review 1.  Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery.

Authors:  Omid Zarei; Silvia Benvenuti; Fulya Ustun-Alkan; Maryam Hamzeh-Mivehroud; Siavoush Dastmalchi
Journal:  J Cancer Res Clin Oncol       Date:  2016-08-08       Impact factor: 4.553

2.  Identification of a RON tyrosine kinase receptor binding peptide using phage display technique and computational modeling of its binding mode.

Authors:  Omid Zarei; Silvia Benvenuti; Fulya Ustun-Alkan; Maryam Hamzeh-Mivehroud; Siavoush Dastmalchi
Journal:  J Mol Model       Date:  2017-08-19       Impact factor: 1.810

3.  Biological function derived from predicted structures in CASP11.

Authors:  Peter J Huwe; Qifang Xu; Maxim V Shapovalov; Vivek Modi; Mark D Andrake; Roland L Dunbrack
Journal:  Proteins       Date:  2016-06-15

4.  Analogs of the hepatocyte growth factor and macrophage-stimulating protein hinge regions act as Met and Ron dual inhibitors in pancreatic cancer cells.

Authors:  Kevin J Church; Brett R Vanderwerff; Rachelle R Riggers; Michelle D McMicheal; Beatriz Mateo-Victoriano; Sudharsan R Sukumar; Joseph W Harding
Journal:  Anticancer Drugs       Date:  2016-09       Impact factor: 2.248

5.  Probing conformational and functional states of human hepatocyte growth factor by a panel of monoclonal antibodies.

Authors:  Masataka Umitsu; Katsuya Sakai; Satoshi Ogasawara; Mika K Kaneko; Ryoko Asaki; Keiko Tamura-Kawakami; Yukinari Kato; Kunio Matsumoto; Junichi Takagi
Journal:  Sci Rep       Date:  2016-09-09       Impact factor: 4.379

6.  Characterizing the Hot Spots Involved in RON-MSPβ Complex Formation Using In Silico Alanine Scanning Mutagenesis and Molecular Dynamics Simulation.

Authors:  Omid Zarei; Maryam Hamzeh-Mivehroud; Silvia Benvenuti; Fulya Ustun-Alkan; Siavoush Dastmalchi
Journal:  Adv Pharm Bull       Date:  2017-04-13

7.  Therapeutic efficacy of a novel humanized antibody-drug conjugate recognizing plexin-semaphorin-integrin domain in the RON receptor for targeted cancer therapy.

Authors:  Xiang-Min Tong; Liang Feng; Sreedhar Reddy Suthe; Tian-Hao Weng; Chen-Yu Hu; Yi-Zhi Liu; Zhi-Gang Wu; Ming-Hai Wang; Hang-Ping Yao
Journal:  J Immunother Cancer       Date:  2019-09-13       Impact factor: 13.751

Review 8.  Targeting RON receptor tyrosine kinase for treatment of advanced solid cancers: antibody-drug conjugates as lead drug candidates for clinical trials.

Authors:  Hang-Ping Yao; Sreedhar Reddy Suthe; Xiang-Min Tong; Ming-Hai Wang
Journal:  Ther Adv Med Oncol       Date:  2020-05-12       Impact factor: 8.168

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.